We are live on ! Find out more
PCSA icon

Processa Pharmaceuticals
PCSA

17 hedge funds and large institutions have $1.28M invested in Processa Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.05% more ownership

Funds ownership: 7.21% → 7.26% (+0.05%)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

6% less funds holding

Funds holding: 18 → 17 (-1)

51% less capital invested

Capital invested by funds: $2.58M → $1.28M (-$1.31M)

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RJFSA
Raymond James Financial Services Advisors
Florida
+$94.7K
2
MCP
Mirador Capital Partners
California
+$41.5K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$7.73K
4
TRCT
Tower Research Capital (TRC)
New York
+$6.76K
5
Renaissance Technologies
Renaissance Technologies
New York
+$4.83K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$111K
2
EIM
Essex Investment Management
Massachusetts
-$5K

PCSA Hedge Fund Activity: Q4 2022 in Review

17 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q4 2022, worth a combined $1.28M — down 51% from $2.58M a quarter earlier.

Fund positioning in PCSA was balanced in Q4 2022: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 0 trimmed.

The largest buyer was Raymond James Financial Services Advisors, opening a new position worth an estimated $94.7K. The largest seller was Morgan Stanley, exiting entirely with an estimated $111K sold.

  • 17 institutional investors held Processa Pharmaceuticals (PCSA) as of Q4 2022, down from 18 in Q3 2022.
  • Funds reported $1.28M of Processa Pharmaceuticals stock for Q4 2022, down 51% quarter-over-quarter.
  • 2 funds opened new Processa Pharmaceuticals positions in Q4 2022 and 2 closed out, a net change of 0 holders.
  • The largest Processa Pharmaceuticals buyer in Q4 2022 was Raymond James Financial Services Advisors, an estimated $94.7K added.
  • The largest Processa Pharmaceuticals seller in Q4 2022 was Morgan Stanley, an estimated $111K sold.

Based on aggregated 13F filings for Q4 2022.